Summary
Bristol Myers Squibb Company (BMY) announced the completion of a significant public offering of debt securities, raising a total of $11.75 billion. This offering includes a variety of notes with fixed and floating interest rates, maturing between 2026 and 2064. The primary purpose of these proceeds is to fund the cash consideration for the proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., along with associated fees and expenses. Any remaining net proceeds will be used for general corporate purposes. The offering was completed as planned, irrespective of the acquisition closings. However, the indenture includes provisions for a Special Mandatory Redemption for most of the notes if the Karuna acquisition is not consummated by specific deadlines or if BMY decides not to pursue it. This offers a degree of protection to noteholders in the event the acquisitions do not proceed, with a redemption price of 101% of the principal amount plus accrued interest.
Key Highlights
- 1BMY completed a public offering of $11.75 billion in aggregate principal amount of notes.
- 2The notes comprise various tranches, including Floating Rate Notes due 2026 and fixed-rate notes maturing from 2026 to 2064.
- 3Proceeds are primarily intended to fund the acquisitions of Karuna Therapeutics and RayzeBio.
- 4The offering was not contingent on the completion of the acquisitions.
- 5A Special Mandatory Redemption clause is in place for most notes if the Karuna acquisition is not completed by certain dates or is abandoned.
- 6The company may redeem most fixed-rate notes early under specific conditions, with varying make-whole provisions or at par after a 'Par Call Date'.
- 7The Floating Rate Notes are not subject to redemption at the company's option.